Acura Pharmaceuticals Price to Book Ratio 2012-2021 | ACUR
Historical price to book ratio values for Acura Pharmaceuticals (ACUR) over the last 10 years. The current price to book ratio for Acura Pharmaceuticals as of June 19, 2026 is 0.00.
| Acura Pharmaceuticals Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-06-17 | 0.00 | 0.15 | |
| 2021-12-31 | 0.50 | $0.00 | 185.19 |
| 2021-09-30 | 0.53 | $0.00 | 250.71 |
| 2021-06-30 | 0.66 | $0.01 | 111.86 |
| 2021-03-31 | 0.33 | $-0.28 | -1.19 |
| 2020-12-31 | 0.21 | $-0.27 | -0.77 |
| 2020-09-30 | 0.25 | $-0.26 | -0.96 |
| 2020-06-30 | 0.35 | $-0.23 | -1.52 |
| 2020-03-31 | 0.28 | $-0.25 | -1.14 |
| 2019-12-31 | 0.23 | $-0.22 | -1.03 |
| 2019-09-30 | 0.30 | $-0.23 | -1.30 |
| 2019-06-30 | 0.14 | $-0.24 | -0.59 |
| 2019-03-31 | 0.18 | $-0.20 | -0.88 |
| 2018-12-31 | 0.11 | $-0.17 | -0.67 |
| 2018-09-30 | 0.19 | $-0.17 | -1.11 |
| 2018-06-30 | 0.36 | $-0.12 | -2.89 |
| 2018-03-31 | 0.51 | $-0.07 | -7.53 |
| 2017-12-31 | 0.40 | $0.00 | -310.69 |
| 2017-09-30 | 0.45 | $0.08 | 5.80 |
| 2017-06-30 | 0.56 | $-0.03 | -20.82 |
| 2017-03-31 | 0.60 | $0.14 | 4.16 |
| 2016-12-31 | 0.77 | $0.10 | 7.66 |
| 2016-09-30 | 1.60 | $-0.04 | -38.74 |
| 2016-06-30 | 1.85 | $0.14 | 13.38 |
| 2016-03-31 | 2.83 | $0.40 | 7.05 |
| 2015-12-31 | 2.50 | $0.67 | 3.73 |
| 2015-09-30 | 2.35 | $0.74 | 3.18 |
| 2015-06-30 | 4.94 | $0.43 | 11.59 |
| 2015-03-31 | 3.95 | $0.67 | 5.93 |
| 2014-12-31 | 2.25 | $0.52 | 4.35 |
| 2014-09-30 | 3.92 | $0.78 | 5.05 |
| 2014-06-30 | 5.45 | $1.05 | 5.17 |
| 2014-03-31 | 7.30 | $1.39 | 5.27 |
| 2013-12-31 | 8.35 | $1.85 | 4.50 |
| 2013-09-30 | 9.50 | $2.14 | 4.45 |
| 2013-06-30 | 9.40 | $2.20 | 4.28 |
| 2013-03-31 | 10.65 | $2.49 | 4.28 |
| 2012-12-31 | 11.10 | $3.01 | 3.69 |
| 2012-09-30 | 8.70 | $3.30 | 2.64 |
| 2012-06-30 | 15.70 | $3.48 | 4.51 |
| 2012-03-31 | 17.30 | $3.67 | 4.71 |
| 2011-12-31 | 17.45 | $4.04 | 4.32 |
| 2011-09-30 | 17.00 | $4.19 | 4.06 |
| 2011-06-30 | 19.35 | $4.40 | 4.40 |
| 2011-03-31 | 15.80 | $2.46 | 6.42 |
| 2010-12-31 | 16.55 | $2.77 | 5.97 |
| 2010-09-30 | 12.45 | $2.97 | 4.19 |
| 2010-06-30 | 12.55 | $3.12 | 4.02 |
| 2010-03-31 | 26.95 | $3.24 | 8.33 |
| 2009-12-31 | 26.65 | $3.42 | 7.79 |
| 2009-09-30 | 25.55 | $3.69 | 6.93 |
| 2009-06-30 | 29.90 | $3.84 | 7.80 |
| 2009-03-31 | 32.10 | $4.37 | 7.35 |
| 2008-12-31 | 36.70 | $4.34 | 8.46 |
| 2008-09-30 | 35.15 | $4.51 | 7.79 |
| 2008-06-30 | 39.75 | $3.97 | 10.01 |
| 2008-03-31 | 43.70 | $3.08 | 14.20 |
| 2007-12-31 | 30.50 | $2.19 | 13.92 |
| 2007-09-30 | 84.00 | $1.06 | 79.29 |
| 2007-06-30 | 55.25 | $-2.05 | -26.96 |
| 2007-03-31 | 42.50 | $-1.92 | -22.09 |
| 2006-12-31 | 37.00 | $-5.78 | -6.40 |
| 2006-09-30 | 32.50 | $-1.55 | -20.92 |
| 2006-06-30 | 30.00 | $-1.29 | -23.26 |
| 2006-03-31 | 36.00 | $-1.11 | -32.34 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Halsey Drug Company, Inc. is engaged in the manufacture, sale and distribution of generic drugs. A generic drug is the chemical and therapeutic equivalent of a brand-name drug for which patent protection has expired. The company sells its generic drug products under its Halsey label and under private-label arrangements with drugstore chains and drug wholesalers. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |